Company news
Invex Therapeutics Ltd. news in 2023
Invex Therapeutics Ltd.'s news releases, calls and decks from 2023, newest first.
Invex and Peptron Mutually Terminate Manufacturing Agreement
December 21, 2023
Invex Granted European Patent for Exenatide in Hydrocephalus
November 21, 2023
Proposed Capital Return to Shareholders of $14.0 Million
November 1, 2023
Invex issued US patent for Traumatic Brain Injury
August 23, 2023
Invex to close IIH Evolve Phase III Clinical Trial
August 20, 2023
Phase III Clinical Trial Update and New IIH Market Analysis
June 27, 2023
Invex Granted European Orphan Drug Designation for TBI
June 22, 2023
Invex Receives Regulatory Approval for IIH EVOLVE in France
April 20, 2023
Israel Ministry of Health Approval for IIH EVOLVE
April 19, 2023
German Approval for IIH EVOLVE Phase 3 Clinical Trial
March 19, 2023
Half Year Accounts
February 16, 2023
First US Clinical Site Activated in IIH EVOLVE Phase III
January 18, 2023